On the 29th, REYON Pharmaceutical (representative directors Sunok Jeong and Yonghwan Yoo) held a groundbreaking ceremony for its mass-production plant for innovative gene therapy at the construction site of the new plant in Chungju City. The groundbreaking ceremony was attended by 160 people, including Chungju Mayor Gilhyeong Cho, Chungju City Council Chairman Jongkap Lee, and ViroMed CEO Yongsu Kim, as well as by the executives and employees of REYON Pharmaceutical.

Representative director Yonghwan Yoo said in a congratulatory remark, “It is our promise to uphold the long-held and grand dream of new drug development held by the late Chairman Seongrak Yoo and all of the family at REYON Pharmaceutical. With the pride of Chungju City and the pride of Korea, the new Chungju factory will leave a giant mark in the global pharmaceutical industry.” He concluded his speech by saying, "We ask for the continued interest and encouragement of all those who made the REYON Pharmaceutical of today a reality, and we will repay your support by growing into one of the world's leading companies.”

An official statement from REYON Pharmaceutical contained the following: "From September 2017 to September 2020, the gene therapy production facilities to be built with a total investment of 80 billion won will be a smart factory utilizing unit production methods conforming to advanced GMP (cGMP, EU-GMP, JGMP, etc.). The raw materials/production processes and the finished product production processes will  be individually united and organically combined according to the amount of production, enabling optimum one-stop production from raw materials to finished products. We will respond flexibly to changes in demand in the raw materials/finished products markets by improving production yield through efficient operation. In the future, we plan to expand facilities in preparation for an increase in the supply of gene therapy products and to sequentially expand production facilities for chemical drugs on the remaining sites."

REYON Pharmaceutical, which holds the worldwide raw material supply rights and the complete distribution rights in Korea or across Asia (excluding Japan) for vascular/neurological disease and anticancer vaccine gene therapy products currently under development, is expecting a quantum jump in sales and profits when its innovative gene therapy products are commercialized.

REYON Pharmaceutical, which has been growing and developing in parallel with the domestic pharmaceutical industry for the past 60 years, achieving localization of drug substances using self-developed fermentation/synthesis technology and conducting continuous research and development through open collaboration, is currently in the spotlight with spectators anticipating how the domestic and overseas pharmaceutical industries will be impacted in the future with its innovative mass production plant for gene therapy products.